Following publication of full Phase I data from its COVID-19 vaccine (jointly developed with the US National Institutes of Health), Moderna, Inc.’s share price has once again shot up, and now stands at $82 a share.
This is a four-fold increase on its pre-pandemic share price in January this year, bringing its market capitalisation to just short of $32bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?